Deep knowledge on
small-molecule drugs and
the 90,000 global patents
|Title:||Nonirritating emulsions for sensitive tissue|
|Abstract:||A pharmaceutical composition is disclosed in the form of a nonirritating emulsion which includes at least one cyclosporin in admixture with a higher fatty acid glyceride and polysorbate 80. More particularly, the cyclosporin may be cyclosporin A and the higher fatty acid glyceride may be castor oil. Composition has been found to be of a high comfort level and low irritation potential suitable for delivery of medications to sensitive areas such as ocular tissues. In addition, the composition has stability for up to nine months without crystallization of cyclosporin.|
|Inventor(s):||Ding; Shulin (Irvine, CA), Tien; Walter L. (Irvine, CA), Olejnik; Orest (Trabuco Canyon, CA)|
|Assignee:||Allergan, Inc. (Irvine, CA)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Publication Date||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|South Korea||100450703||Sep 20, 2004|
|China||1229136||Nov 30, 2005|
|Australia||693213||Jun 25, 1998|
|China||1198587||Apr 27, 2005|
|Austria||203911||Aug 15, 2001|
|This preview shows a limited data set|
Subscribe for full access, or try a free trial
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.